LLY vs SERA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
SERA presents a contradictory profile with a stable Piotroski F-Score of 6/9 but catastrophic operational metrics. While the balance sheet remains lean with very low debt (D/E 0.03) and adequate liquidity, the company is experiencing a severe revenue collapse (-58.3% YoY) and negative gross margins (-102.47%), indicating that the cost of producing its services exceeds the revenue generated. The extreme Price-to-Sales ratio (1111.49) and aggressive insider selling suggest a lack of confidence in the current business model, rendering the single analyst's 'strong buy' rating highly speculative.
Compare Another Pair
Related Comparisons
LLY vs SERA: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Sera Prognostics, Inc. (SERA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.